Clinical trials: Growth Hormone Disorder
Growth Hormone Deficiency
A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device
This is a Phase IV, open label, case-controlled, observational study to evaluate the age-adjusted cumulative height velocity in pre-pubertal isolated growth hormone deficient (IGHD) and idiopathic short stature (ISS) participants…
- Trial name
- NCT01243892
- Testing
- NuSpin, Somatropin
- Where
- 14 sites in United States
- Volunteers
- 18 people
- Sponsor
- Genentech, Inc.
Chronic Kidney Disease, End-Stage Renal Disease
Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease
This trial is conducted in Asia, Europe, and Middle East. Adult patients with chronic kidney disease are treated with growth hormone to assess effect on nutritional status.
- Trial name
- NCT00184652
- Testing
- somatropin
- Where
- 26 sites in Denmark, Germany and 7 more
- Volunteers
- 140 people
- Sponsor
- Novo Nordisk A/S
HIV Infections, HIV Wasting Syndrome
Growth Hormone in the Treatment of HIV-Associated Wasting
The purpose of this study is to compare physical function and lean body mass in patients getting different doses of somatropin compared to patients not getting the drug.
- Trial name
- NCT00489528
- Testing
- Somatropin; Recombinant human growth hormone (r hGH)
- Sponsor
- EMD Serono
Acromegaly
Acromegaly Treatment Quality of Life Study
The investigators hypothesize that treatment of acromegaly will be associated with an improvement in quality of life compared to active acromegaly.
- Trial name
- NCT01732406
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Massachusetts General Hospital
Growth Hormone Deficiency
Fluids Administration During Combined Clonidine-Arginine Growth Hormone Stimulation Test
The diagnosis of Growth Hormone deficiency in childhood requires the performance of an artificial pharmacological stimulation tests.
- Trial name
- NCT04465565
- Testing
- 9% Sodium Chloride (NaCl) IV
- Where
- Israel
- Sponsor
- Rabin Medical Center
Breast Cancer, Breast Cancer Metastatic
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers.
- Conditions
- Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Trial name
- INX-315-01 (NCT05735080)
- Testing
- INX-315, Fulvestrant, Abemaciclib
- Where
- 18 sites in United States, Australia
- Volunteers
- 150 people
- Sponsor
- Incyclix Bio
Acromegaly, Insulin Resistance
Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients
The purpose of this study is to investigate if co-treatment of acromegalic patients, who beforehand are considered well-controlled on SA monotherapy, with pegvisomant and SA will improve insulin sensitivity and glucose tolerance…
- Conditions
- Acromegaly, Insulin Resistance, Impaired Glucose Tolerance
- Trial name
- NCT00652379
- Testing
- Pegvisomant, Somatostatin analog (lanreotide or octreotide)
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- University of Aarhus
Dwarfism, Pituitary
National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients
This study is a multicenter, open-label, observational, postmarketing surveillance study that will collect information on the use of Genentech GH preparations to treat GH-deficient subjects with optimal GH dosing during puberty.
- Trial name
- NCT00097513
- Where
- United States
- Sponsor
- Genentech, Inc.
Traumatic Brain Injury
Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.
Growth Hormone (GH) deficiency, defined by insufficient GH response to a variety of stimulating compounds, is found in 20-35% of adults who suffer traumatic brain injuries (TBI) requiring inpatient rehabilitation1.
- Trial name
- Growth-TBI (NCT00766038)
- Testing
- Recombinant human Growth Hormone
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- University of Pennsylvania
Acromegaly
Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
The purpose of this study was to assess the safety, tolerability, and efficacy of IONIS-GHR-LRx in up to 60 participants with acromegaly.
- Trial name
- NCT03548415
- Testing
- IONIS-GHR-LRx
- Where
- 33 sites in United States, Hungary and 5 more
- Volunteers
- 43 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Cystic Fibrosis
Growth Hormone Treatment Study in Children With Cystic Fibrosis
Cystic fibrosis (CF) is a catabolic condition, and children affected with this disease frequently have problems with growth, despite adequate nutrition.
- Trial name
- NCT00256555
- Testing
- Nutropin AQ
- Sponsor
- University of Texas Southwestern Medical Center
Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
- Trial name
- ELUCIDATE (NCT05985655)
- Testing
- GTAEXS617, SoC
- Where
- 15 sites in United States, Belgium and 1 more
- Volunteers
- 230 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Growth Hormone Deficiency
Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)
This is a multi-national trial. The goals of the trial are to study the growth response to LUM-201 administration in children with idiopathic growth hormone deficiency (GHD) previously treated with daily rhGH for 12 months in the…
- Trial name
- OraGrowtH213 (NCT05250063)
- Testing
- LUM-201
- Where
- 10 sites in United States, Poland
- Volunteers
- 15 people
- Sponsor
- Lumos Pharma